Literature DB >> 32071939

Localization of Salivary Glands for Botulinum Toxin Treatment: Ultrasound Versus Landmark Guidance.

Sebastian Loens1, Norbert Brüggemann1,2, Armin Steffen3, Tobias Bäumer1.   

Abstract

BACKGROUND: Sialorrhea is a troublesome symptom in a variety of neurological diseases. Recently, local injection of botulinum toxin into the salivary glands was approved for treatment of sialorrhea, and injection guidance by anatomical landmarks was suggested.
OBJECTIVE: To compare the accuracy of ultrasound versus previously proposed anatomical landmarks for localizing the salivary glands.
METHODS: In a cross-sectional study in 21 adults, landmark positions (LM) of the parotid gland (PG) and the submandibular gland (SG) were identified following published recommendations. The ultrasound position (US) was defined as the position representing the maximum gland thickness. The distance between positions, gland thickness, and optimal injection depth were recorded by US.
RESULTS: Gland thickness differed significantly between LM and US positions (PG, 4 vs. 17.8 mm; P < 0.001; SG, 3.5 vs. 13.6 mm; P < 0.001). The spatial deviation between the recommended LM and identified US positions in the horizontal plane was 21 mm to the posterior direction for the PG and 19.6 mm for the SG. The deviation in vertical orientation was small for both glands; however, there was a positive correlation between the distance from the SG to the mandibular bone with age. The optimal injection depth measured by US was 11.8 mm for the PG and 13.6 mm for the SG. This showed to be positively correlated with the body mass index.
CONCLUSIONS: The position of the salivary glands differs from proposed landmarks and depends on the individual age and body weight; therefore, we recommend ultrasound guidance for injection.
© 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  botulinum toxin; hypersalivation; sialorrhea; ultrasound

Year:  2019        PMID: 32071939      PMCID: PMC7011800          DOI: 10.1002/mdc3.12881

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  12 in total

1.  Impact of drooling in Parkinson's disease.

Authors:  Johanna G Kalf; Anne M Smit; Bastiaan R Bloem; Machiel J Zwarts; Marten Munneke
Journal:  J Neurol       Date:  2007-08-02       Impact factor: 4.849

2.  Anatomical localization of submandibular gland for botulinum toxin injection.

Authors:  J H Lee; B N Lee; S O Kwon; R H Chung; S H Han
Journal:  Surg Radiol Anat       Date:  2010-03-11       Impact factor: 1.246

Review 3.  Hypersalivation: update of the German S2k guideline (AWMF) in short form.

Authors:  Armin Steffen; Wolfgang Jost; Tobias Bäumer; Dirk Beutner; Sabine Degenkolb-Weyers; Martin Groß; Maria Grosheva; Samer Hakim; Kai G Kahl; Rainer Laskawi; Rebekka Lencer; Jan Löhler; Thekla Meyners; Saskia Rohrbach-Volland; Rainer Schönweiler; Sara-Christina Schröder; Sebastian Schröder; Heidrun Schröter-Morasch; Maria Schuster; Susanne Steinlechner; Roland Urban; Orlando Guntinas-Lichius
Journal:  J Neural Transm (Vienna)       Date:  2019-04-10       Impact factor: 3.575

4.  Ultrasound-guided botulinum toxin injections for treatment of drooling.

Authors:  R Breheret; A Bizon; C Jeufroy; L Laccourreye
Journal:  Eur Ann Otorhinolaryngol Head Neck Dis       Date:  2011-05-19       Impact factor: 2.080

Review 5.  Management of oral secretions in neurological disease.

Authors:  Alexander J McGeachan; Christopher J Mcdermott
Journal:  Pract Neurol       Date:  2017-02-10

6.  Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease.

Authors:  Okan Dogu; Demir Apaydin; Serhan Sevim; Derya Umit Talas; Mihriban Aral
Journal:  Clin Neurol Neurosurg       Date:  2004-03       Impact factor: 1.876

Review 7.  Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead.

Authors:  Leslie J Blackhall
Journal:  Muscle Nerve       Date:  2012-03       Impact factor: 3.217

8.  Botulinum toxin A for children with salivary control problems.

Authors:  Jenny Montgomery; Sarah McCusker; Jane Hendry; Eleanor Lumley; Haytham Kubba
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2014-09-06       Impact factor: 1.675

9.  Botulinum toxin in the treatment of sialorrhea.

Authors:  Marina Svetel; Milan Vasić; Natasa Dragasević; Tatjana Pekmezović; Igor Petrović; Vladimir Kostić
Journal:  Vojnosanit Pregl       Date:  2009-01       Impact factor: 0.168

10.  SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.

Authors:  Wolfgang H Jost; Andrzej Friedman; Olaf Michel; Christian Oehlwein; Jaroslaw Slawek; Andrzej Bogucki; Stanislaw Ochudlo; Marta Banach; Fernando Pagan; Birgit Flatau-Baqué; János Csikós; Claire J Cairney; Andrew Blitzer
Journal:  Neurology       Date:  2019-03-27       Impact factor: 9.910

View more
  3 in total

1.  [Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults].

Authors:  Wolfgang H Jost; Tobias Bäumer; Andrea Bevot; Ulrich Birkmann; Carsten Buhmann; Maria Grosheva; Orlando Guntinas-Lichius; Ute Mlynczak; Sebastian Paus; Christina Pflug; Sebastian Schröder; Armin Steffen; Bernd Wilken; Steffen Berweck
Journal:  Fortschr Neurol Psychiatr       Date:  2022-04-22       Impact factor: 0.760

Review 2.  Sialorrhea in Parkinson's Disease.

Authors:  Jonathan Isaacson; Sanskruti Patel; Yasar Torres-Yaghi; Fernando Pagán
Journal:  Toxins (Basel)       Date:  2020-10-31       Impact factor: 4.546

3.  Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection.

Authors:  Joerg Mueller; Thomas Langbein; Aditi Mishra; Richard P Baum
Journal:  Toxins (Basel)       Date:  2022-01-17       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.